NCT05099978 2024-09-04
A-TRAIN
National Cancer Center, Japan
Unknown
Clinical Trials
1,001 trialsNCT06128694 2024-07-30
Effect of NUTRICAN to Improve Nutritional Status in Cancer Patients
Kalbe International Pte. Ltd
Phase 3 Unknown
NCT06270706 2024-06-12
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Pliant Therapeutics, Inc.
Phase 1 Unknown
NCT03425565 2024-04-12
PEACOCC
University College, London
Phase 2 Unknown
NCT06308406 2024-04-11
A Phase Ib/II Clinical Study of HRS-1167 in Combination With Bevacizumab in Patients With Recurrent Ovarian Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2 Unknown
NCT05143970 2024-03-20
CHANCES
Institut Paoli-Calmettes
Phase 1 Unknown
NCT04780217 2024-03-04
Intravenous T3011 Given as a Single Agent and in Combination With Other Therapy in Subjects With Advanced Solid Tumors
ImmVira Pharma Co. Ltd
Phase 1/2 Unknown
NCT06284980 2024-02-29
TITANIUM
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Unknown
NCT04512209 2024-02-28
DCE-MRI
University Hospital, Ghent
Phase NA Unknown
NCT06031493 2024-02-28
PROVIDENCE
Hospital Clinic of Barcelona
Phase 4 Unknown
NCT06279832 2024-02-28
Romantic
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase NA Unknown
NCT06281860 2024-02-28
PITHAC
Centre Hospitalier Universitaire Vaudois
Phase 1 Unknown
NCT05371223 2024-02-26
Nab-PIPAC
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase 2 Unknown
NCT06277947 2024-02-26
GARD-HIPEC
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase NA Unknown
NCT06278636 2024-02-26
LUXA
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Unknown
NCT05701735 2024-02-23
CECIL
University of Santo Tomas Hospital, Philippines
Phase NA Unknown
NCT05728814 2024-02-23
DORA
Grupo Español de Investigación en Cáncer de Ovario
Unknown
NCT06124040 2024-02-23
SUCCEEDER
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Unknown
NCT06273878 2024-02-23
From Fetal-maternal Interface Immune Tolerance to Endometrial Cancer Immune Escape: Potential Targets for Immunotherapy
Regina Elena Cancer Institute
Unknown
NCT06274541 2024-02-23
Upfront Systematic Tumour BRCA Testing in Patients With High Grade Serous or Endometrioid Ovarian, Fallopian Tube or Primary Peritoneal Cancer (HGSEC): The t-BRCA Study
Cancer Trials Ireland
Unknown
NCT05737797 2024-02-22
NIECE
Assistance Publique - HĂ´pitaux de Paris
Phase NA Unknown
NCT06273501 2024-02-22
POSVUC
Sahlgrenska University Hospital
Phase NA Unknown
NCT03924466 2024-02-16
VUBAR
Universitair Ziekenhuis Brussel
Phase 2 Unknown
NCT06263062 2024-02-16
Management With Fear of Cancer in Women Undergoing Colposcopy: Randomized Controlled Study
Alanya Alaaddin Keykubat University
Phase NA Unknown
NCT06261892 2024-02-15
Non-invasive Biomarker Discovery for Pre-cervical or/and Cervical Cancer-HPV DNA and Other Biomarkers in Urine
WomenX Biotech Limited
Phase NA Unknown
NCT04145388 2024-02-14
Family History Study on Cancer Risk
Kaiser Permanente
Phase NA Unknown
NCT02730923 2024-02-13
VICTORIA
Centre Leon Berard
Phase 1/2 Unknown
NCT05829057 2024-02-13
The IIT Study of Evaluation of P-IL-2 Single Agent and With Anti-PD-1
Zhejiang University
Phase 1 Unknown
NCT06250686 2024-02-09
BENITA
Universitätsklinikum Hamburg-Eppendorf
Phase NA Unknown
NCT02820506 2024-02-08
SENTIREC II
University of Southern Denmark
Phase NA Unknown
NCT03549273 2024-02-07
Evaluation Glizigen® and Ocoxin®-Viusid® in High-grade Cervical Intraepithelial Lesions
Catalysis SL
Phase 2 Unknown
NCT04149691 2024-02-07
Safety, Tolerability and Pharmacokinetics of Oral CPL304110, in Adult Subjects With Advanced Solid Malignancies
Celon Pharma SA
Phase 1 Unknown
NCT06069648 2024-02-07
Effects of Decision Aids on the Participation of South Asian Women in Cervical Cancer Screening
Chinese University of Hong Kong
Phase NA Unknown
NCT05189028 2024-02-06
Study of Neoadjuvant Chemotherapy Versus Definite Concurrent Chemoradiotherapy for Locally Advanced Bulk Cervical Cancer
Shantou University Medical College
Phase 3 Unknown
NCT06243185 2024-02-06
Dalpiciclib Combined With Letrozole in HR+/HER2 - Gynecologic Solid Tumors
Peking Union Medical College Hospital
Phase 2 Unknown
NCT06241105 2024-02-05
Lenvatinib Plus Toripalimab for Platinum-Resistant Recurrent Ovarian Cancer
Peking Union Medical College Hospital
Phase 2 Unknown
NCT05212779 2024-02-01
Predicting the Risk of Ovarian Cancer Recurrence Using Circulating Tumor DNA to Assess Residual Disease
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Unknown
NCT06208319 2024-02-01
IACOL
Assistance Publique - HĂ´pitaux de Paris
Unknown
NCT06236958 2024-02-01
Effect of Early Enteral Nutrition on Postoperative Recovery of Ovarian Cancer Patients
The First Affiliated Hospital with Nanjing Medical University
Unknown
NCT03016338 2024-01-30
Study of Niraparib and TSR-042 in Recurrent Endometrial Cancer
University Health Network, Toronto
Phase 2 Unknown
NCT04470921 2024-01-26
STOPOVCA
Radboud University Medical Center
Unknown
NCT05489926 2024-01-26
A Study to Explore Pamiparib Treatment in Epithelial Ovarian Cancer After Prior PARP Inhibitor Exposure
Zhejiang Cancer Hospital
Phase 2 Unknown
NCT06223308 2024-01-25
A Study Evaluating the Safety and Efficacy of HB0028 in Subjects With Advanced Solid Tumors
Shanghai Huaota Biopharmaceutical Co., Ltd.
Phase 1/2 Unknown
NCT06223763 2024-01-25
SUROVA
Clinica Universidad de Navarra, Universidad de Navarra
Unknown
NCT03515993 2024-01-24
Follow-up in Gynecological Cancer Survivors
European Organisation for Research and Treatment of Cancer - EORTC
Unknown
NCT06222008 2024-01-24
Study on Symptom Clusters During Chemotherapy in Ovarian Cancer Patients With Different Chinese Medicine Constitution
Affiliated Hospital of Jiaxing University
Unknown
NCT05916690 2024-01-19
Electrochemotherapy for the Treatment of Vulvar Cancer
Institute of Oncology Ljubljana
Phase NA Unknown
NCT05084677 2024-01-18
Toripalimab Combined With Concurrent Chemoradiotherapy in Cervical Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT02489006 2024-01-17
NEO
University Health Network, Toronto
Phase 2 Unknown
NCT05065021 2024-01-17
Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor
University Health Network, Toronto
Phase 2 Unknown